Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096110 | 0.93 | ADRB3 (0.81) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7096869 | 0.90 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091464 | 0.87 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7095903 | 0.87 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7094593 | 0.85 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7699697 | 0.85 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7142391 | 0.84 | ADRB3 (0.73) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7094681 | 0.84 | ADRB3 (0.79) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7701777 | 0.83 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7092794 | 0.83 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007036543-A1 | BETA-3-AGONIST USE FOR TREATING KIDNEY AND BLADDER TROUBLES OF A PATIENT WITH SPINAL CORD DAMAGES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.